H R Wiltshire, K. J. Prior, J. Dhesi
Feb 1, 2001
Citations
0
Influential Citations
2
Citations
Journal
Journal of Labelled Compounds and Radiopharmaceuticals
Abstract
The development of the collagenase inhibitor, cipemastat (Ro 32-3555), required the synthesis of both carbon-14 labelled and deuteriated material for the measurement of the parent drug and drug-related material in biological fluids. In addition, labelled metabolites were needed for both in vitro metabolism and analytical studies. This paper describes the synthesis of labelled forms of cipemastat and its amide (Ro 32-4778) and glucuronide (Ro 32-6414) metabolites. Copyright © 2001 John Wiley & Sons, Ltd.